CD8A and neoplasm: Using previously described, functionally validated gene signatures (neoTCR8 and neoTCR4 for CD8+ and CD4+ T cells, respectively)4, we then performed single-cell gene set enrichment analysis to predict the tumor antigen reactivity of T cells in the tumor (predicted-reactive T cells).